



ATOMO DIAGNOSTICS LIMITED
ACN 142 925 684

Notice of Annual General Meeting

Explanatory Statement and Proxy Form

Date of Meeting:
Thursday, 5 November 2026

Time of Meeting:
10:00am (AEDT)

The meeting will be held by live webcast via:
Zoom webinar

The meeting will be held virtually via a webinar conferencing facility. If you are a shareholder who wishes to attend and participate in the virtual meeting, please register in advance as per the instructions outlined in this Notice of Meeting. Shareholders are strongly encouraged to lodge their completed proxy forms in accordance with the instructions in this Notice of Meeting.

This Notice of Annual General Meeting and Explanatory Statement should be read in its entirety. If shareholders are in doubt as to how they should vote, they should seek advice from their accountant, solicitor or other professional advisor without delay.

ATOMO DIAGNOSTICS LIMITED

ACN 142 925 684

Registered office: Level 1, 3-5 George St. Leichhardt NSW 2040

NOTICE OF ANNUAL GENERAL MEETING

Notice is given that the Annual General Meeting (“**AGM**” or “**Meeting**”) of Members of Atomo Diagnostics Limited (the “**Company**”) will be held by video-conferencing facility at 10:00am (AEDT) on Thursday, 5 November 2026.

The technology used to hold the Meeting virtually will provide Shareholders with a reasonable opportunity to ask questions or make comments. Voting at the Meeting is occurring by way of poll rather than a show of hands. Each person entitled to vote is to be given the opportunity to vote in real time, and this Notice of Meeting includes information about how shareholders can participate in the Meeting. Shareholders attending virtually will be taken for all purposes to be in attendance as if they were physically there.

Shareholders are encouraged to submit their proxies as early as possible and in any event prior to the cut-off for proxy voting as set out in the Notice. To lodge your proxy, please follow the directions on your personalised proxy form.

Shareholders who wish to participate in the AGM online may register in advance for the Meeting:

https://vistra.zoom.us/webinar/register/WN_CLGwUIGLSiWUuPGaVPjFZQ

When: Thursday, 5 November 2026 at 10:00am (AEDT)

Topic: Atomo Diagnostics Limited – 2026 Annual General Meeting

After registering, you will receive a confirmation email containing information about joining the Meeting. The Company strongly recommends its Shareholders to lodge a direct proxy as soon as possible in advance of the Meeting even if they are planning to attend the Meeting online.

The Company is happy to accept and answer questions submitted prior to the Meeting by email to the Company Secretary Mathew Watkins, mathew.watkins@vistra.com. Where a written question is raised in respect to the key management personnel (“KMP”) of the Company and/or the Resolutions to be considered at the Meeting, the Company will address the relevant question during the course of the Meeting or by written response after the Meeting (subject to the discretion of the Company not to respond to unreasonable and/or offensive questions).

Any Shareholder wishing to attend the AGM online should therefore monitor the Company’s website and its ASX announcements for any updates about the AGM. If it becomes necessary or appropriate to make alternative arrangement for the holding or conduct of the Meeting, the Company will make further information available through the ASX website at www.asx.com.au (ASX: AT1) and on its website at <https://investors.atomodiagnostics.com/investor-centre/>.

AGENDA

The Explanatory Statement and proxy form, which accompany and form part of this Notice, include defined terms and describe in more detail the matters to be considered. Please consider this Notice, the Explanatory Statement and the proxy form in their entirety.

ORDINARY BUSINESS

Receipt and Consideration of Financial Statements & Reports

To receive and consider the 2026 Annual Report of the Company and its controlled entities for the financial year ended 30 June 2026, which includes the Financial Report, the Directors' Report and the Auditor's Report.

Note: Except for as set out in Resolution 1, there is no requirement for shareholders to approve these reports. Accordingly, no resolution will be put to shareholders on this item of business.

Resolution 1: Adoption of Remuneration Report

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

"That for the purpose of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report (included in the Directors' report) for the financial year ended 30 June 2026 be adopted."

Resolution 2: Re-election of Mr Patrick Cook as a Director of the Company

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

"That, for the purpose of Rule 20.6 of the Constitution and for all other purposes, Mr Patrick Cook who retires by rotation as a Director in accordance with the Constitution of the Company, and who, being eligible, offers himself for re-election, be re-elected as a Director of the Company."

Resolution 3: Ratification of prior issue of 90,909,091 Ordinary Shares and 45,454,536 Options, as part of the Placement

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

*"That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders approve, ratify and confirm the allotment and issue of 90,909,091 fully paid ordinary shares ("**Shares**") in the Company on 8 April 2026 at an issue price of \$0.033 (3.3 cents) per Share and 45,454,536 free attaching unlisted options ("**Options**") in relation to the Placement to professional, sophisticated and other exempt investors as described in the Explanatory Statement."*

Resolution 4: Ratification of prior issue of Broker Options to Joint Lead Managers

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

*"That, for the purposes of Listing Rule 7.4 and for all other purposes, shareholders approve, ratify and confirm the issue and allotment of 5,000,000 Broker Options ("**Options**") in the Company to Joint Lead Managers, at an exercise price of \$0.045 (4.5 cents) per Option, as part consideration on the terms and conditions set out in the Explanatory Statement."*

Resolution 5: Ratification of prior issue of 1,348,480 Ordinary Shares and 674,229 Options, as part of the Share Purchase Plan (SPP)

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

*"That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders approve, ratify and confirm the allotment and issue of 1,348,480 fully paid ordinary shares ("**Shares**") in the Company on 15 May 2026 at an issue price of \$0.033 (3.3 cents) per Share and 674,229 free attaching unlisted options ("**Options**") in relation to the Share Purchase Plan ("**SPP**") as described in the Explanatory Statement."*

Resolution 6: Approval of Employee Option Plan

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

"That for the purposes of ASX Listing Rule 7.2 Exception 13(b) and for all other purposes, approval is given for the Company to issue Equity Securities under the Company's Employee Option Plan as an exception to Listing Rule 7.1 on the terms and conditions as set out or described in the Explanatory Statement which accompanies and forms part of this Notice of Meeting."

Resolution 7: Approval to Grant Options to Mr Patrick Cook (and/or his nominee(s))

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 10.14 and for all other purposes, approval be given to grant 1,400,000 Options in the Company to Mr Patrick Cook, (and/or his nominee(s)), Non-Executive Chair of the Company, on the terms and conditions set out in the Explanatory Statement accompanying the Notice of Meeting."

Resolution 8: Approval to Grant Options to Mr Anthony May (and/or his nominee(s))

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 10.14 and for all other purposes, approval be given to grant 1,000,000 Options in the Company to Mr Anthony May (and/or his nominee(s)), Non-Executive Director of the Company, on the terms and conditions set out in the Explanatory Statement accompanying the Notice of Meeting."

Resolution 9: Approval to Grant Options to Dr Cheri Walker (and/or her nominee(s))

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:

"That, for the purposes of Listing Rule 10.14 and for all other purposes, approval be given to grant 700,000 Options in the Company to Dr Cheri Walker (and/or her nominee(s)), Interim Managing Director of the Company, on the terms and conditions set out in the Explanatory Statement accompanying the Notice of Meeting."

SPECIAL BUSINESS

Resolution 10: Approval of 10% Placement Facility

To consider and, if thought fit, pass the following resolution as a **special resolution**:

"That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, shareholders approve the issue of Equity Securities up to the equivalent of 10% of the Company's fully paid ordinary issued capital (at the time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions in the Explanatory Statement."

By the order of the Board



Mathew Watkins
Company Secretary
25 September 2026

Notes

1. **Entire Notice:** The details of the resolutions contained in the Explanatory Statement accompanying this Notice of Meeting should be read together with, and form part of, this Notice of Meeting.
2. **Record Date:** The Company has determined that for the purposes of the Annual General Meeting, shares will be taken to be held by the persons who are registered as holding the shares at 7.00pm (AEDT), 48 hours before the date of the AGM. Only those persons will be entitled to vote at the AGM and transfers registered after that time will be disregarded in determining entitlements to attend and vote at the AGM.
3. **Proxies**
 - a. Votes at the AGM may be given personally or by proxy, attorney or representative.
 - b. Each member has a right to appoint one or two proxies.
 - c. A proxy need not be a member of the Company.
 - d. If a member is a company it must execute under its common seal or otherwise in accordance with its constitution or the Corporations Act.
 - e. Where a shareholder is entitled to cast two or more votes, the shareholder may appoint two proxies and may specify the proportion or number of votes each proxy is appointed to exercise.
 - f. If a shareholder appoints two proxies, and the appointment does not specify the proportion or number of the shareholder's votes, each proxy may exercise half of the votes. If a shareholder appoints two proxies, neither proxy may vote on a show of hands.
 - g. A proxy must be signed by the shareholder or his or her attorney who has not received any notice of revocation of the authority. Proxies given by corporations must be signed in accordance with corporation's constitution and Corporations Act.
 - h. To be effective, proxy forms must be received by the Company's share registry no later than 48 hours before the commencement of the AGM, this is no later than 10:00am (AEDT) on Tuesday, 3 November 2026. Any proxy received after that time will not be valid for the scheduled Meeting.

4. Corporate Representative

Any corporate shareholder who has appointed a person to act as its corporate representative at the Meeting should provide that person with a certificate or letter executed in accordance with the Corporations Act authorising him or her to act as that company's representative. The authority may be sent to the Company and/or share registry in advance of the Meeting or handed in at the Meeting when registering as a corporate representative.

5. Voting Exclusion Statement:

Resolution 1

In accordance with sections 250R(4) and 250BD(1) of the Corporations Act, a vote must not be cast (in any capacity), and the Company will disregard any votes purported to be cast, on this Resolution by, or on behalf of, a member of the Key Management Personnel ("KMP"), details of whose remuneration are included in the remuneration report, or a Closely Related Party of such a member (either being a "KMP voter"), unless the KMP voter is casting a vote on behalf of a person who is not a KMP voting (including as a proxy) and either:

- a. the KMP voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution; or
- b. the KMP voter is by the Chair of the Meeting and the appointment of the Chair as proxy:
 - i. does not specify the way the proxy is to vote on the Resolution; and
 - ii. expressly authorises the Chair to exercise the proxy even if the Resolution is connected directly or indirectly with the remuneration of a member of the key KMP for the Company or the consolidated entity.

If you appoint the Chair as your proxy and you do not direct the Chair on how to vote, you will be expressly authorising the Chair to exercise the proxy even if the relevant Resolution is connected directly or indirectly with the remuneration of a member of the KMP for the Company.

If the Chair of the Meeting is appointed as a proxy for a person who is permitted to vote on this Resolution, the Chair will vote any proxies which do not indicate on their proxy form the way the Chair must vote, in favour of the Resolution. In exceptional circumstances, the Chair may change their voting intention on the Resolution, in which case an ASX announcement will be made. Shareholders may also choose to direct the Chair to vote against the Resolution or to abstain from voting.

If you purport to cast a vote other than as permitted above, that vote will be disregarded by the Company (as indicated above) and you may be liable for breaching the voting restrictions that apply to you under the Corporations Act.

A further restriction also applies to KMP and their Closely Related Party voting undirected proxies on this Resolution – see Restriction on KMPs voting undirected proxies below.

Resolution 2

There are no voting exclusions on this Resolution.

Resolutions 3 – 5

The Company will disregard any votes cast in favour of these Resolutions by or on behalf of any person, and any associates of that person, who participated in the issue of securities participated in the issue of securities including Company's Joint Lead Managers, Alpine Capital Pty Ltd and GBA Capital Pty Ltd.

However, this does not apply to a vote cast in favour of the Resolution by:

- (a) a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to the proxy or attorney to vote on the Resolution in that way; or
- (b) the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a direction given to the Chair to vote on the Resolution as the Chair decides; or
- (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - i. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the Resolution; and
 - ii. the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Resolutions 6

The Company will disregard any votes cast in favour of this Resolution by any person eligible to participate in the Company's Employee Option Plan, and any of their associates.

However, this does not apply to a vote cast in favour of the resolution by:

- (a) a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the proxy or attorney to vote on the resolution in that way; or
- (b) the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given to the chair to vote on the resolution as the chair decides; or
- (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - i. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the resolution; and
 - ii. the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

A vote must not be cast as proxy on this Resolution by a KMP voter. However, a KMP voter may cast a vote on behalf of a person who is not a KMP voter if:

- (a) the KMP voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution; or
- (b) the KMP voter is by the Chair of the Meeting and the appointment of the Chair as proxy:
 - i. does not specify the way the proxy is to vote on the Resolution; and
 - ii. expressly authorises the Chair to exercise the proxy even if the Resolution is connected directly or indirectly with the remuneration of a member of the key KMP for the Company or the consolidated entity.

If you appoint the Chair as your proxy and you do not direct the Chair on how to vote, you will be expressly authorising the Chair to exercise the proxy even if the relevant Resolution is connected directly or indirectly with the remuneration of a member of the KMP for the Company.

If the Chair of the Meeting is appointed as a proxy for a person who is permitted to vote on this Resolution, the Chair will vote any proxies which do not indicate on their proxy form the way the Chair must vote, in favour of the Resolution. In exceptional circumstances, the Chair may change their voting intention on the Resolution, in which case an ASX announcement will be made. Shareholders may also choose to direct the Chair to vote against the Resolution or to abstain from voting.

If you purport to cast a vote other than as permitted above, that vote will be disregarded by the Company (as indicated above) and you may be liable for breaching the voting restrictions that apply to you under the Corporations Act.

Resolutions 7 – 9

The Company will disregard any votes cast in favour of each of Resolutions 7 through to 9 (respectively and separately) by or on behalf of

- Mr Patrick Cook, Mr Anthony May, Dr Cheri Walker or any person(s) who will obtain a material benefit as a result of the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the entity), or
- an associate of person referred to in the preceding paragraph.

However, this does not apply to a vote cast in favour of the resolution by:

- (a) a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to the proxy or attorney to vote on the resolution in that way; or
- (b) the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction given to the chair to vote on the resolution as the chair decides; or
- (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met:
 - i. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on the resolution; and
 - ii. the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Furthermore, a vote must not be cast as proxy on any Resolutions 7, 8 and 9 by a member of the Key Management Personnel (as defined by the Corporations Act) or a closely related party of Key Management Personnel.

Resolution 10

As at the date of despatch of this Notice, the Company does not have approval to make an issue of Equity Securities under Listing Rule 7.1A.2 and, therefore, a voting exclusion statement on this Resolution is not required by Listing Rule 7.3A.7 as at that date.

This is a Special Resolution requiring at least 75% of the votes cast by Shareholders entitled to vote to be in favour of the Resolution in order for it to pass.

6. Restriction on KMPs voting undirected proxies:

A vote must not be cast as proxy on Resolution 1 or Resolution 6 by a member of the KMP (as defined by the Corporations Act) or a Closely Related Party of a KMP.

However, a person described above (a "**Restricted Voter**") may cast a vote on behalf of a person who is not a Restricted Voter on Resolution 1 or Resolution 6 as a proxy if:

- (a) The Restricted Voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution(s); or
- (b) The Chair is the Restricted Voter and the written appointment of the Chair as proxy does not specify the way the proxy is to vote on the Resolution(s) or expressly authorises the Chair to exercise the proxy even though the Resolution(s) is connected directly or indirectly with the remuneration of a member of the KMP.

If you appoint the Chair as your proxy and you do not direct the Chair how to vote, you will be expressly authorising the Chair to exercise the proxy even if the relevant Resolution(s) is connected directly or indirectly with the remuneration of a member of the KMP for the Company.

7. Enquiries

Shareholders are invited to contact the Company Secretary on (03) 9692 7222 if they have any queries in respect of the matters set out in these documents.

EXPLANATORY STATEMENT

Purpose of Information

This Explanatory Statement ("**Statement**") accompanies and forms part of the Company's Notice of Annual General Meeting ("**Notice**") for the 2026 Annual General Meeting ("**Meeting**") will be held by video-conferencing facility at 10.00am (AEDT) on Thursday, 5 November 2026.

The Notice incorporates, and should be read together, with this Statement.

Receipt and consideration of Accounts & Reports

A copy of the Annual Report for the financial year ended 30 June 2026 (which incorporates the Company's financial report, reports of the Directors (including the Remuneration Report) and the auditors) the Company's website <https://investors.atomodiagnosics.com/investor-centre/?page=financial-reports> or via the Company's announcement platform on ASX. Alternatively, you may obtain a copy free of charge in hard copy form by contacting the Company by phone at 02 9099 4750 and you may request that this occurs on a standing basis for future years. There is no requirement for Shareholders to approve the Annual Report.

Shareholders will have the opportunity at the Meeting to ask questions about or make comments on the 2026 Financial Report, the Directors' Report, and the Auditor's Report. Questions for the Company's auditors relating to the conduct of the audit, preparation and contents of the audit report, accounting policies adopted by the Company in relation to the preparation of its financial statements, and the independence of the auditors in relation to the conduct of the audit, must be submitted no later than 5 business days before the Meeting to the Company Secretary at the Company's registered office. The auditor will be invited to attend and answer questions about the audit of the Company's 2026 Annual Financial Statements.

ORDINARY BUSINESS

Resolution 1: Adoption of Remuneration Report

Background

Section 250R (2) of the Corporations Act requires that a resolution to adopt the Remuneration Report must be put to the vote at the Annual General Meeting. The vote on this Resolution is advisory only and does not bind the Directors or the Company.

The Remuneration Report is set out in the Directors' Report in the Company's 2026 Annual Report. The Remuneration Report sets out the Company's remuneration arrangements for the Directors and senior management of the Company.

In accordance with section 250SA of the Corporations Act, shareholders will be provided with a reasonable opportunity to ask questions concerning, or make comments on, the Remuneration Report at the AGM.

In accordance with Division 9 of Part 2G.2 of the Corporations Act, if twenty five (25%) per cent or more of votes that are cast are voted against the adoption of the Remuneration Report at two consecutive Annual General Meetings, shareholders will be required to vote at the second of those Annual General Meetings on a resolution (a "**spill resolution**") that another meeting be held within 90 days at which all of the Company's Directors (other than the Managing Director) must go up for re-election.

At its last annual general meeting, a Spill Resolution was put to shareholders, as a result of there having been two consecutive Annual General Meetings (including the last annual general meeting) at which at least 25% of the votes cast on the Remuneration Report resolution were cast against the Remuneration Report Resolution. The Spill Resolution put to shareholders at the last annual general meeting was not passed by shareholders therefore a Spill Resolution is not relevant for this Annual General Meeting.

The Directors will consider the outcome of the vote and comments made by Shareholders on the Remuneration Report at the Meeting when reviewing the Company's remuneration policies.

Board Recommendation

Noting that each Director has a personal interest in their own remuneration from the Company (as such interests are described in the Remuneration Report) and, as described in the voting exclusions on this Resolution (set out in the Notice of AGM), that each Director (or any Closely Related Party of a Director) is excluded from voting their shares on this Resolution, the Directors encourages all eligible shareholders to cast their votes in favour of this Resolution.

Voting Intention

The Chair intends to vote all undirected proxies in favour of this resolution.

Voting Exclusions

A voting exclusion statement for this resolution is set out in Note 5 and 6 above.

Resolution 2: Re-election of Mr Patrick Cook as a Director of the Company

Background

Clause 20.6 of the Constitution of the Company requires that at each annual general meeting one third of the Directors (except for the managing director) shall retire from office by rotation. The Directors to retire in every year shall be those who have been longest in office since their last election.

Mr Cook was appointed Non-executive Director on 2 May 2025. Mr Cook is an experienced Non-Executive Director and Chair with over 35 years experience as a senior executive in medical devices & point-of-care diagnostics sectors within various multinational, private and listed biotechnology companies. Currently serves as Non-Executive Director at Workplace Drug Testing Australasia Ltd and as a Committee Member at Animal Ethics Committee QUT. Previously served as Non- Executive Director & Chair at eWaste Connection Ltd, Board Member at Prostate Cancer Foundation of Australia (Qld), a Fellow of the Australian Institute of Company Directors and holds degrees in Science and Marketing.

The Company considers Mr Cook as an independent director for all purposes.

Board Recommendation

The Board (with Mr Cook abstaining in his capacity as a Director) recommends that shareholders vote in favour of this Resolution as it considers that Mr Cook 's qualifications, experience, skills, and expertise are appropriate for the Board position and will enable him to act in the best interests of the Company and its shareholders.

Voting Intention

The Chair intends to vote all undirected proxies in favour of this Resolution.

Voting Exclusions

There are no voting exclusions on this Resolution.

Background to Resolutions 3 to 5

On 30 March 2026, the Company announced that it was undertaking a capital raising to raise up to approximately \$4.0 million, by way of Placement to raise \$3.0 million ("**Placement**") and Share Purchase Plan ("**SPP**") to raise up to 1.0 million (together known as "**Capital Raising**").

On 8 April 2026, the Company issued 90,909,091 new fully paid ordinary shares ("**Shares**") at an issue price of \$0.033 (3.3 cents) per share with 45,454,536 free attaching options, exercisable at \$0.045 (4.5 cents) expiring 2.5 years from the date of issue, on the basis of one option for every two new shares subscribed for and issued ("**Options**").

The Placement was undertaken by the Company with Joint Lead Managers, Alpine Capital Pty Ltd and GBA Capital Pty Ltd (“JLM’s”). On 8 April 2026, the JLM’s received 5,000,000 Broker Options issued on the same terms as the Placement and SPP free attaching options.

On 15 May 2026, the Company issued 1,348,480 Shares and 674,229 Options (“SPP Securities”) to existing shareholders, on the same terms as that of the placement participants. The SPP Securities were offered under a Prospectus, the Company is not relying on ASX Listing Rule 7.2 (Exception 5) and therefore will seek approval to ratify.

The Placement, SPP and associated resolutions are summarized below:

- Resolution 3: Ratification of prior issue of 90,909,091 Ordinary Shares and 45,454,536 Options, as part of the Placement
- Resolution 4: Ratification of prior issue of Broker Options to Joint Lead Managers
- Resolution 5: Ratification of prior issue of 1,348,480 Ordinary Shares and 674,229 Options, as part of the Share Purchase Plan (SPP)

Resolution 3: Ratification of prior issue of 90,909,091 Ordinary Shares and 45,454,536 Options, as part of the Placement

Background

As noted above, the Company is seeking shareholder approval pursuant to ASX Listing Rule 7.4 to ratify the issue of 90,909,091 Shares in the Company at an issue price of \$0.033 (3.3 cents) per Share and 45,454,536 Options, on 8 April 2026 on the terms as announced on 30 March 2026 (“Placement Securities”).

The Shares and Options were issued without shareholder approval out of the Company’s 15% placement capacity pursuant to ASX Listing Rule 7.1 and 10% placement capacity pursuant to ASX Listing Rule 7.1A.

Listing Rules

ASX Listing Rules 7.1 allow the Company to issue new securities up to 15% of the existing capital of the Company in any 12-month period without the prior approval of Shareholders, unless one of the exceptions in ASX Listing Rule 7.2 applies. The issuance of the Placement Securities were within the Company’s available placement capacity under ASX Listing Rules 7.1.

ASX Listing Rule 7.1A provides that a Company may seek shareholder approval at its annual general meeting to issue additional quoted securities up to 10% of its issued capital, provided that it is an eligible entity (Eligible Entity).

An Eligible Entity is one that, as at the date of the relevant annual general meeting:

- a) it must have a market capitalisation of \$300 million or less.
- b) it must not be included in the S&P/ASX 300 Index.

At the time the approval was obtained (the Company’s last Annual General Meeting 31 October 2025), the Company was an Eligible Entity.

Under ASX Listing Rule 7.4 an issue of securities will be treated as having been made with the approval of shareholders for the purposes of ASX Listing Rules 7.1 and 7.1A if the issue did not breach ASX Listing Rules 7.1 & 7.1A at the time and shareholders subsequently approve it. The Company now seeks Shareholder ratification of the issue pursuant to ASX Listing Rule 7.4 in order to retain as much flexibility as possible to issue additional equity securities into the future without having to obtain shareholder approval for such issues under Listing Rules 7.1 and 7.1A.

If the Resolution is approved, the prior issue of Placement Securities will be excluded from the calculation of the number of equity securities the Company can issue without Shareholder approval under ASX Listings Rule 7.1 and 7.1A. The Company will therefore have the flexibility, if required, to issue additional equity securities without the Placement Securities counting towards the 25% threshold for the purposes of ASX Listing Rules 7.1 and 7.1A.

If this Resolution is not approved, the prior issue of Placement Securities will be included in the calculation of the number of equity securities the Company can issue without Shareholder approval under ASX Listing Rules 7.1 and 7.1A. The Company will therefore have the Placement Securities, as counting towards the 25% threshold for the purposes of ASX Listing Rules 7.1 and 7.1A.

ASX Listing Rule 7.5 requires that the following information be provided to Shareholders for the purpose of obtaining Shareholder approval pursuant to ASX Listing Rule 7.4:

- i. the Shares were issued to institutional and sophisticated professional investors selected through the networks of the JLM's;
- ii. the number and class of securities issued were 90,909,091 fully paid ordinary shares and 45,454,536 options, issued on 8 April 2026;
- iii. the 90,909,091 fully paid ordinary shares were issued at a price of \$0.033 (3.3 cents) per Share;
- iv. the 45,454,536 free attaching options were issued, with an exercise price of \$0.045 (4.5 cents) per Option, expiring 2.5 years from the date of issue. The material terms of Options are set out in Annexure A;
- v. the purpose of the issue was to raise funds for expanding commercialisation of the Company's own portfolio of proprietary diagnostic tests, including Active Syphilis and Liver function, deliver operational scale up to support increased demand for supply of Pascal cassettes for Lumos' FebriDx growth in the US and working capital alongside costs of the Capital Raising. The issue of Options will not raise any funds however if any Options are exercised in the future, the funds raised will be used to on the business activities at that time;
- vi. the purpose of the issue of the free-attaching Options was to incentivise the participants in the Placement.

Board Recommendation

The Board recommends that shareholders vote in favour of this Resolution.

Voting Intention

The Chair intends to vote all undirected proxies in favour of this Resolution.

Voting Exclusions

A voting exclusion statement for this resolution is set out in Note 5 above.

Resolution 4: Ratification of prior issue of Broker Options to Joint Lead Managers

Background

As noted above, the Company is seeking shareholder approval pursuant to ASX Listing Rule 7.4 to ratify issue of 5,000,000 Broker Options in the Company to JLM's.

The Placement was undertaken by the Company's Joint Lead Managers, Alpine Capital Pty Ltd and GBA Capital Pty Ltd (together, the "**JLM's**"). The JLM's received a 6% broker fee on all funds raised in addition to 5,000,000 Broker Options ("**Broker Options**"), issued on 8 April 2026, on the same terms as the Placement and SPP free attaching options.

Listing Rules

ASX Listing Rules 7.1 allow the Company to issue new securities up to 15% of the existing capital of the Company in any 12-month period without the prior approval of Shareholders, unless one of the exceptions in ASX Listing Rule 7.2 applies. The issuance of the Broker Options were within the Company's available placement capacity under ASX Listing Rules 7.1.

Under ASX Listing Rule 7.4 an issue of securities will be treated as having been made with the approval of shareholders for the purposes of ASX Listing Rule 7.1 if the issue did not breach ASX Listing Rule 7.1 at the time

and shareholders subsequently approve it. The Company now seeks Shareholder ratification of the issue pursuant to ASX Listing Rule 7.4 in order to retain as much flexibility as possible to issue additional equity securities into the future without having to obtain shareholder approval for such issues under Listing Rule 7.1.

If the Resolution is approved, the prior issue of Broker Options will be excluded from the calculation of the number of equity securities the Company can issue without Shareholder approval under ASX Listing Rule 7.1. The Company will therefore have the flexibility, if required, to issue additional equity securities without the Broker Options counting towards the 15% threshold for the purposes of ASX Listing Rule 7.1.

If this Resolution is not approved, the prior issue of Broker Options will be included in the calculation of the number of equity securities the Company can issue without Shareholder approval under ASX Listing Rules 7.1. The Company will therefore have the Broker Options, as counting towards the 15% threshold for the purposes of ASX Listing Rule 7.1.

ASX Listing Rule 7.5 requires that the following information be provided to Shareholders for the purpose of obtaining Shareholder approval pursuant to ASX Listing Rule 7.4:

- (a) Alpine Capital Pty Ltd and GBA Capital Pty Ltd are the Joint Lead Managers to the Placement;
- (b) the 5,000,000 Broker Options were issued on 8 April 2026 to the Joint Lead Managers, in consideration for the lead manager services provided;
- (c) the 5,000,000 Broker Options were issued, with an exercise price of \$0.045 (4.5 cents) per Option, expiring 2.5 years from the date of issue. The material terms of Options are set out in Annexure A; and
- (d) the purpose of the issue of the Broker Options was to incentivise the JLM in the Placement. The issue of Options will not raise any funds however if any Options are exercised in the future, the funds raised will be used to on the business activities at that time
- (e) the Broker Options were issued to JLM under an engagement letter, the material terms of which are:
The Company will pay to the joint lead manager in their Respective Proportions:
 - (i) Management fee of 2% of total funds raised under the offer for the placement and the SPP – to be split equally between the JLMs; and
 - (ii) Capital Raising fee of 4% on funds raised by the joint lead managers – to be split equally between the JLMs; and
 - (iii) Five million (5,000,000) Lead Manager Options on the same terms as the Attaching Options issued under the Placement.
 - The cost price of the options is \$0.000001
 - The issuance of the options will be subject to shareholder approval at an upcoming general meeting.
 - The options will be split equally between the JLMs.

Board Recommendation

The Board recommends that shareholders vote in favour of this Resolution.

Voting Intention

The Chair intends to vote all undirected proxies in favour of this Resolution.

Voting Exclusions

A voting exclusion statement for this resolutions is set out in Note 5 above.

Resolution 5: Ratification of prior issue of 1,348,480 Ordinary Shares and 674,229 Options, as part of the Share Purchase Plan (SPP)

Background

As noted above, the Company is seeking shareholder approval pursuant to ASX Listing Rule 7.4 to ratify the issue of 1,348,480 Shares in the Company. at an issue price of \$0.033 (3.3 cents) per Share and 674,229 Options, on 15 May 2026 on the terms as announced on 30 March 2026 ("**SPP Securities**").

The Shares and Options were issued without shareholder approval from the Company's 15% placement capacity.

Listing Rules

Listing Rule 7.1 allows the Company to issue new securities up to 15% of the existing capital of the Company in any 12-month period without the prior approval of shareholders, unless one of the exceptions in Listing Rule 7.2 applies. The shares issued were within the Company's available placement capacity under ASX Listing Rules 7.1.

Under ASX Listing Rule 7.4 an issue of securities will be treated as having been made with the approval of shareholders for the purposes of ASX Listing Rule 7.1 if the issue did not breach Listing Rule 7.1 at the time and shareholders subsequently approve it. The issue of the SPP Securities were within the Company's Listing Rule 7.1, did not fall within any of the exceptions in Listing Rule 7.2, and were not previously approved by Shareholders. The Company now seeks Shareholder approval of the issue of SPP Securities pursuant to Listing Rule 7.4.

If this Resolution is approved, the prior issue of SPP Securities will be excluded in calculating the Company's 15% limit in Listing Rule 7.1, effectively increasing the number of equity securities it can issue without shareholder approval over the 12 month period following the issue date.

If this Resolution is not approved, the prior issue of SPP Securities will be included in calculating the Company's 15% limit in Listing Rule 7.1, effectively decreasing the number of equity securities it can issue without shareholder approval over the 12 month period following the issue date.

Listing Rule 7.5 requires that the following information be provided to Shareholders for the purpose of obtaining shareholder approval pursuant to ASX Listing Rule 7.4:

- (a) the SPP Securities were issued to existing shareholders who held shares at the relevant record date;
- (b) the number and class of securities issued were 1,348,480 Ordinary Shares and 674,229 Options, issued on 15 May 2026;
- (c) the 1,348,480 fully paid ordinary shares were issued at a price of \$0.033 (3.3 cents) per Share.
- (d) the 674,229 free attaching options were issued, with an exercise price of \$0.045 (4.5 cents) per Option, expiring 2.5 years from the date of issue. The material terms of Options are set out in Annexure A;
- (e) the purpose of the issue was to raise funds for expanding commercialisation of the Company's own portfolio of proprietary diagnostic tests, including Active Syphilis and Liver function, deliver operational scale up to support increased demand for supply of Pascal cassettes for Lumos' FebriDx growth in the US and working capital alongside costs of the Capital Raising. The issue of Options will not raise any funds however if any Options are exercised in the future, the funds raised will be used to on the business activities at that time; and
- (f) the purpose of the issue of the free-attaching Options was to incentivise the participants in the SPP.

Board Recommendation

The Board recommends that Shareholders vote in favour of this Resolution.

Voting Intention

The Chair intends to vote all undirected proxies in favour of this Resolution.

Voting Exclusions

A voting exclusion statement for this Resolution is set out in Note 5 above.

Resolution 6: Approval of Employee Option Plan

Background

The Company's Employee Option Plan ("**Plan**") was last approved by the Shareholders at the Company's 2023 Annual General Meeting.

Resolution 6 seeks Shareholder approval to 'renew' the Company's Employee Option Plan whereby the issuing capacity has reduced since the issued capacity approval at the 2023 Annual General Meeting.

The approval of the Plan is sought pursuant to Listing Rule 7.2, Exception 13(b), sections 295B(2) and 260C(4) of the Corporations Act.

The Board is committed to incentivising and retaining the Company's employees (including a director employed in an executive capacity) and such other persons as the Board determine, in a manner which promotes alignment of their interests with Shareholder interests. Additionally, the Board considers equity-based compensation an integral component of the Company's remuneration platform as it allows it to be fiscally prudent by conserving cash resources while still enabling it to offer market-competitive remuneration arrangements.

If Shareholders approve this Resolution, the Company will have the ability to issue options or performance rights (together **Awards**) (and shares on exercise of Awards) under the Plan will not be included in the 15% limit imposed by ASX Listing Rule 7.1 for a period of three years from the date of the AGM.

If this Resolution is not approved by Shareholders, any Awards (and shares on exercise of Awards) issued by the Company under the Plan will be included in the formula to calculate the number of securities which the Company may issue in any 12- month period using ASX Listing Rule 7.1 ("15% Placement Capacity")

Listing Rules

Listing Rule 7.1 requires that Shareholder approval is required for an issue of securities if the securities will, when aggregated with the securities issued by the entity during the previous 12 months, exceed 15% of the number of securities on issue at the commencement of that 12-month period.

Listing Rule 7.2 exception 13(b) provides an exception to Listing Rule 7.1 for securities issued under an employee incentive scheme, such as the EIP, within 3 years after Shareholder approval of the issue of Equity Securities under that scheme as an exception to Listing Rule 7.1. The Company therefore seeks approval of the issue of Equity Securities under the EIP pursuant to Listing Rule 7.2 Exception 13(b) to refresh its capacity under so that issues of securities under the EIP do not impede the capacity of the Company to issue up to a further 15% of its capital without Shareholder approval.

Corporations Act

Approval is also sought for the purposes of sections 259B and 260C of the Corporations Act to allow maximum flexibility and to avoid any technical Corporations Act issues.

Section 259B(1) of the Corporations Act provides that a company must not take security over Shares in itself except as permitted by the Corporations Act. Section 259B(2) of the Corporations Act provides that the Company may take security over Shares in itself under an employee share scheme that has been approved by Shareholders at a general meeting.

Under section 260C(4) of the Corporations Act, a company may financially assist a person to acquire its Shares if the financial assistance is given under an employee share scheme that is approved by Shareholders at a general meeting.

Information required for Listing Rule 7.2, exception 13(b)

- (a) A summary of the terms of the Plan is set out in Annexure B below. There have been no material changes to the terms of the Option Plan as disclosed in the Company's IPO Prospectus.

- (b) The maximum number of equity securities proposed to be issued under the Plan over the next three years following shareholder approval is 45,000,000.
- (c) 8,100,000 equity securities have been issued under the Plan since the date of its adoption.

Board Recommendation

The Board recommends that shareholders vote in favour of this Resolution.

Voting Intention

The Chair intends to vote all undirected proxies in favour of this resolution.

Voting Exclusions

A voting exclusion statement for this resolution is set out in Note 5 and 6 above.

Resolutions 7 - 9: Approval to Grant Options to Directors of the Company

Background

Resolutions 7, 8, and 9 of this Notice seeks shareholder approval for the grant of a total of 3,100,000 unlisted options (**Options**) in the Company to its Directors, on the terms described below, as well as Shareholder approval for the issue of any corresponding Shares of the Company on the vesting and the exercise of those Options. These Options are proposed to be issued to the following Directors:

Table 1

Resolution	Option Recipients	Position	Number of options ("Director Options")
7	Mr Patrick Cook (and/or his nominee)	Non-Executive Chair	1,400,000
8	Mr Anthony May (and/or his nominee)	Non-Executive Director & Chair of Audit & risk Committee	1,000,000
9	Dr Cheri Walker (and/or her nominee)	Interim Managing Director	700,000
		Total	3,100,000

The Options are proposed to be granted to the Directors to align their interests with the interests of Shareholders. The grant of the Options (and the subsequent issue of Shares, once the vesting conditions are met) to Mr Patrick Cook, Mr Anthony May and Dr Cheri Walker is a cash retentive form of remuneration when compared to the payment of cash consideration.

Terms of Options and Remuneration package

The following details are provided in respect of the proposed issue of Options:

Table 2

Name of the Allotee (Director or their appointed nominee)	Number of Options (in separate tranches with vesting conditions)	Exercise Price	Vesting Condition	Expiry Date	Remuneration Package
Mr Patrick Cook (Resolution 7)	1,400,000	\$0.017	The Options will vest and become exercisable subject to Mr Cook holding a Non-Executive Director position in the Company as at 30 June 2027.	24 months from the date of Vesting of the Options	\$50,000 and is eligible to participate in the Company's long-term incentive arrangements on terms decided by the Board, subject to necessary shareholder approvals.
Mr Anthony May (Resolution 8)	1,000,000	\$0.017	The Options will vest and become exercisable subject to Mr May holding a Non-Executive Director position in the Company as at 30 June 2027.	24 months from the date of Vesting of the Options	\$50,000 and is eligible to participate in the Company's long-term incentive arrangements on terms decided by the Board, subject to necessary shareholder approvals.
Dr Cheri Walker (Resolution 9)	700,000	\$0.017	The Options will vest and become exercisable subject to Dr Walker holding a Director position in the Company as at 30 June 2027.	24 months from the date of Vesting of the Options	\$445,000 for Interim Chief Executive Officer position (on an annualised basis noting the initial term was for 6 months with the ability to extend), \$50,000 for Director position, and is eligible to participate in the Company's long-term incentive arrangements on terms decided by the Board, subject to necessary shareholder approvals.
Total	3,100,000				

Consistent with the desire to minimise cash expenditures, the Board believes that in order to incentivise Mr Cook, Mr May and Dr Walker, in line with current market practices, Options provide an appropriate and meaningful remuneration component to Director's that is aligned with Shareholder interests.

No Voting Rights

The Options do not confer:

- the right to participate in any dividends paid by the Company;
- a right to notices of general meetings of the Company, except as required by law;
- a right to attend or speak at general meetings of the Company;
- a right to vote at any general meetings of the Company; or
- a right to participate in new issues of securities in the Company.

Value of the Proposed Director Options

The total value the entity attributes to these Options is \$52,700 based off the market price of the Company's quoted Shares on 16 September 2026 being \$0.017 (1.7 cents).

The Company has prepared an indicative fair value of the Options as summarised below. The values are indicative only based on assumptions relevant at the date of the calculation (Date). Different assumptions may be relevant at grant date which may alter the value of the Director Options for financial reporting purposes. The total remuneration packages for each of the above Allottee Directors would be increased by the total per Director set out in the following table, based on the assumptions. The final valuation amount will not be able to be calculated until the Options are issued.

Table 3

Allottee Director (and/or associates)	Number of Options	Indicative Fair Value
Mr Patrick Cook (and/or nominee)	1,400,000	\$23,800
Mr Anthony May (and/or nominee)	1,000,000	\$17,000
Dr Cheri Walker (and/or nominee)	700,000	\$11,900
TOTAL	3,100,000	\$52,700

As of 16 September 2026, the Directors have the following direct and indirect interests in Shares and options in the Company:

Table 4

Allottee Directors (and/or associates)	Current Holdings as of 16 September 2026 of this Notice of Meeting	
	Shares	Options
Mr Patrick Cook	717,909	1,940,541
Mr Anthony May	540,541	1,240,541
Dr Cheri Walker	-	1,000,000

The exercise of the Options proposed to be granted under Resolutions 7 - 9 (assuming no other exercise of options or issue of securities other than those proposed for the Directors under Resolutions 7 - 9), would result in holdings for each of the Director and a dilution of all other Shareholders' holdings in the Company based on the issued capital as of 16 September 2026 as follows:

Table 5

Director/Shareholder (and/or associate(s))	Total Current Shareholdings		Shares issued if proposed options issued and exercised	Total Shareholdings if proposed options issued and exercised	
	Shares	%	# Shares	Shares	%
Mr Patrick Cook	717,909	0.08%	1,400,000	2,117,909	0.23%
Mr Anthony May	540,541	0.06%	1,000,000	1,540,541	0.17%
Dr Cheri Walker	-	-	700,000	7,000	0.08%
Other Shareholders	901,174,403	99.86%		901,174,403	99.52%
TOTAL:	902,432,853	100.00%	3,100,000	905,532,853	100.00%

Corporations Act

Reasonable Remuneration - Sections 208 & 211

Section 228 of the Corporations Act defines a “related party” for the purposes of Chapter 2E to include a Director of the public company. A “financial benefit” is defined in section 229 of the Corporations Act and includes granting Options to a related party. Mr Cook, Mr May and Dr Walker are Directors of the Company and thus are related parties for the purposes of Chapter 2E of the Corporations Act.

The Board has formed the view that the grant of Options to Mr Cook, Mr May and Dr Walker as above, does not require Shareholder approval under section 208 of the Corporations Act as the grant constitute “reasonable remuneration” in accordance with section 211 of the Corporations Act. Accordingly, the Board is not seeking Shareholder approval under section 208 of the Corporations Act, although Shareholder approval must be obtained pursuant to Listing Rule 10.14.

In reaching this view, and consistent with the desire to minimise cash expenditures, the Board believes that having regard to the current market practices the Board considers that the proposed grant of Options aligns the interests of Mr Cook, Mr May and Dr Walker with the interests of Shareholders. The grant of Options to Mr Cook, Mr May and Dr Walker is a cost-effective form of remuneration when compared to the payment of cash consideration.

The Company believes it is appropriate to grant the Options to Mr Cook, Mr May and Dr Walker. Smaller entities with limited cash resources often elect to use equity instruments to remunerate directors to attract and retain high calibre individuals while minimising the cash cost of engaging those people.

Consistent with the desire to minimise cash expenditures, the Board believes that having regard to the current market practices, the Performance Rights provide an appropriate and meaningful remuneration component to Mr Cook, Mr May and Dr Walker that is aligned with Shareholder interests.

ASX Listing Rule 10.14

The Company is proposing to issue the Options under the EIP which is an employee incentive scheme as defined in the Listing Rules.

Listing Rule 10.14 provides that a listed company must not permit any of the following persons to acquire equity securities under an employee incentive scheme:

- 10.14.1: a director of the company;
- 10.14.2: an associate of a director of the company; or
- 10.14.3: a person whose relationship with the company or a person referred to in Listing Rule 10.14.1 or 10.14.2 is such that, in ASX's opinion, the acquisition should be approved by its Shareholders,

unless it obtains the approval of its Shareholders.

The proposed issue of the Options falls within Listing Rules 10.14.1 above and therefore requires the approval of the Company's Shareholders under Listing Rule 10.14.

Resolution 7-9 seeks the required Shareholder approval to the issue under and for the purposes of Listing Rule 10.14.

If Resolutions 7,8 and 9 are passed, the Company will be able to proceed with the issue of a total of 3,100,000 Options (being 1,400,000 Option to Mr Cook, 1,000,000 Options to Mr May and 700,000 Options to Dr Walker).

If Resolutions 7,8 and 9 are not passed, the Company will not proceed with the issue of a total of 3,100,000 Options (being 1,400,000 Option to Mr Cook, 1,000,000 Options to Mr May and 700,000 Options to Dr Walker).

If approval is given under ASX Listing Rule 10.14 approval is not required under ASX Listing Rule 7.1.

The following information is given under ASX Listing Rule 10.15 in respect of the proposed issues of Options :

- (a) the Options are proposed to be issued to Mr Patrick Cook, Mr Anthony May and Dr Cheri Walker (or their respective nominees);
- (b) the approval for Mr Patrick Cook, Mr Anthony May and Dr Cheri Walker is sought under ASX Listing Rule 10.14.1, being Directors, and therefore related parties, of the Company;
- (c) the total number and class of securities proposed to be issued are 3,100,000 Options (being 1,400,000 Option to Mr Cook, 1,000,000 Options to Mr May and 700,000 Options to Dr Walker);
- (d) a summary of the material terms of the Options are set out below and will, upon exercise, entitle the holder to one fully paid ordinary share in the Company:

Table 6

	Options
Number	3,100,000
Exercise Price	\$0.017
Vesting Conditions	The Recipient holding a Director position in the Company as at 30 June 2027.
Expiry Date	2 years from the date of vesting

- (e) the Company is issuing Options as a form of equity security as a cost effective, non-cash incentive to the Directors;
- (f) the value the Company attributes to the Director Options is set out on the pages above;
- (g) the entity expects to issue the Options within one month after the date of the meeting, and in any event, no later than 3 years after the date of the meeting;
- (h) the Options will be issued as remuneration and to compensate for the additional duties of the Non-Executive Directors without expending cash. As such there is no issue price for the Options, and the Company will not receive cash from issue of the Options;
- (i) a summary of the material terms of the EIP is included in Annexure B;
- (j) no loans will be made to Mr Cook, Mr May or Dr Walker or their nominee in relation to the acquisition of the Options;
- (k) 3,100,000 Options were issued for nil consideration under the EIP on 12 December 2025, being 1,400,000 Option to Mr Cook, 700,000 Options to Mr May and 1,000,000 Options to Dr Walker.
- (l) details of any securities issued under the EIP will be published in the annual report of the Company relating to the period in which they were issued, along with a statement that approval for the issue was obtained under Listing Rule 10.14. No securities have previously been issued to the Allottee Directors under the EIP;
- (m) any additional persons covered by Listing Rule 10.14 who become entitled to participate in an issue of securities under the EIP after Resolution 7, 8 and 9 are approved and who are not named in this Notice and Statement will not participate until approval is obtained under that rule.

Board Recommendation

The Board (with Mr Cook, Mr May and Dr Walker abstaining in relation to each of their own Options) recommends that shareholders vote in favour of Resolutions 7, 8 and 9.

The Chair of the Meeting intends to vote undirected proxies in favour of this Resolution.

Voting Exclusions

A voting exclusion statement for this Resolution is set out in Note 5 above.

SPECIAL BUSINESS

Resolution 10: Approval of 10% Placement Facility

Background

Listing Rule 7.1A enables eligible entities to issue Equity Securities up to 10% of its issued share capital through placements over a 12-month period after the Annual General Meeting ("**10% Placement Facility**"). The 10% Placement Facility is in addition to the Company's 15% placement capacity under Listing Rule 7.1.

An eligible entity for the purposes of Listing Rule 7.1A is an entity that is not included in the S&P/ASX 300 Index and has a market capitalisation of \$300 million or less. The Company is an eligible entity.

This Resolution seeks Shareholder approval by way of a special resolution to have the ability, if required, to issue Equity Securities under the 10% Placement Facility. The effect of this Resolution will be to allow the Company to issue Equity Securities under Listing Rule 7.1A during the 10% Placement Period without any further Shareholder approval, in addition to the Company's 15% placement capacity under Listing Rule 7.1.

If Shareholders approve this Resolution, the number of Equity Securities permitted to be issued under the 10% Placement Facility will be determined in accordance with the formula prescribed in Listing Rule 7.1A.2 (see below).

If this Resolution is not passed, the Company will not be able to access the additional 10% capacity to issue equity securities without Shareholder provided for in Listing Rule 7.1A and will remain subject to the 15% limit on issuing equity securities without Shareholder approval set out in Listing Rule 7.1.

This Resolution is a special resolution and therefore requires approval of 75% of the votes cast by Shareholders present and eligible to vote at this Meeting (in person, by proxy, by attorney or, in the case of a corporate Shareholder, by a corporate representative).

Listing Rules information

Listing Rule 7.1A enables eligible entities to issue Equity Securities up to the equivalent of 10% of the company's fully paid ordinary issued capital through placements over a 12-month period after the Annual General Meeting ("**10% Placement Facility**"). The 10% Placement Facility is in addition to the Company's 15% placement capacity under Listing Rule 7.1.

An eligible entity for the purposes of Listing Rule 7.1A is an entity that is not included in the S&P/ASX 300 Index and has a market capitalisation of \$300 million or less. The Company is an eligible entity.

This Resolution seeks Shareholder approval by way of a special resolution to have the ability, if required, to issue Equity Securities under the 10% Placement Facility. The effect of Resolution 5 will be to allow the Company to issue Equity Securities under Listing Rule 7.1A during the 10% Placement Period without any further Shareholder approval, in addition to the Company's 15% placement capacity under Listing Rule 7.1.

If Shareholders approve this Resolution, the number of Equity Securities permitted to be issued under the 10% Placement Facility will be determined in accordance with the formula prescribed in Listing Rule 7.1A.2 (see below).

If this Resolution is not passed, the Company will not be able to access the additional 10% capacity to issue equity securities without Shareholder approval provided for in Listing Rule 7.1A and will remain subject to the 15% limit on issuing equity securities without Shareholder approval set out in Listing Rule 7.1.

Resolution is a special resolution and therefore requires approval of 75% of the votes cast by Shareholder's present and eligible to vote at this Meeting (in person, by proxy, by attorney or, in the case of a corporate Shareholder, by a corporate representative).

Description of Listing Rule 7.1A

(a) Shareholder approval

The ability to issue Equity Securities under the 10% Placement Facility is subject to Shareholder approval by way of a special resolution at an Annual General Meeting. This means it requires approval of 75% of the votes cast

by Shareholder's present and eligible to vote (in person, by proxy, by attorney or, in the case of a corporate Shareholder, by a corporate representative).

(b) Equity Securities

Any Equity Securities issued under the 10% Placement Facility must be in the same class as an existing quoted class of Equity Securities of the Company.

The Company, as at the date of the Notice, has on issue one class of quoted Equity Securities, only Fully Paid Ordinary Shares.

(c) Formula for calculating 10% Placement Facility

Listing Rule 7.1A.2 provides those eligible entities which have obtained Shareholder approval at an Annual General Meeting may issue or agree to issue, during the 12-month period after the date of the Annual General Meeting, a number of Equity Securities calculated in accordance with the following formula:

$$(A \times D) - E$$

A is the number of shares on issue at the commencement of the "relevant period" (which, for the Company, is the 12 month period immediately preceding the date of the issue or agreement):

- A. plus the number of fully paid shares issued in the relevant period under an exception in Listing Rule 7.2, other than exception 9, 16 or 17;
- C. plus the number of fully paid shares issued in the relevant period on the conversion of convertible securities within rule 7.2 exception 9 where:
 - (i) the convertible securities were issued or agreed to be issued before the commencement of the relevant period; or
 - (ii) the issue of, or agreement to issue, the convertible securities was approved, or taken under the Listing Rules to have been approved, under rule 7.1 or rule 7.4;
- C. plus the number of fully paid shares issued in the relevant period under an agreement to issue securities within rule 7.2 exception 16 where:
 - (i) the agreement was entered into before the commencement of the relevant period; or
 - (ii) the agreement or issue was approved, or taken under the Listing Rules to have been approved, under rule 7.1 or rule 7.4;
- D. plus the number of fully paid shares issued in the relevant period with approval under Listing Rules 7.1 or 7.4;
- E. plus the number of partly paid shares that became fully paid in the relevant period;
- F. less the number of fully paid shares cancelled in the relevant period.

Note that A has the same meaning in Listing Rule 7.1 when calculating an entity's 15% placement capacity.

D is 10%

E is the number of Equity Securities issued or agreed to be issued under Listing Rule 7.1A.2 in the relevant period where the issue or agreement has not been subsequently approved by Shareholders under Listing Rule 7.1 or 7.4.

(d) Listing Rule 7.1 and Listing Rule 7.1A

The ability of an entity to issue Equity Securities under Listing Rule 7.1A is in addition to the entity's 15% placement capacity under Listing Rule 7.1.

The actual number of Equity Securities that the Company will have capacity to issue under Listing Rule 7.1A will be calculated at the date of issue of the Equity Securities in accordance with the formula prescribed in Listing Rule 7.1A.2 (refer above).

(e) Nature of consideration for issue and Minimum Issue Price

The Equity Securities issued under Listing Rule 7.1A must be issued for a cash consideration per security which must be not less than 75% of the VWAP of Equity Securities in the same class calculated over the 15 trading days on which trades in that class were recorded immediately before:

- (i) the date on which the price at which the Equity Securities are to be issued is agreed by the Company and the recipient of the securities; or
- (ii) if the Equity Securities are not issued within 10 trading days of the date in paragraph (i) above, the date on which the Equity Securities are issued.

(f) 10% Placement Period

Shareholder approval of the 10% Placement Facility under Listing Rule 7.1A commences on the date of the Annual General Meeting at which the approval is obtained and expires on the first to occur of the following:

- i. the date that is 12 months after the date of the Annual General Meeting at which the approval is obtained;
- ii. the time and date of the Company's next annual general meeting; and
- iii. the time and date of the approval by Shareholders of a transaction under Listing Rules 11.1.2 (a significant change to the nature or scale of activities) or 11.2 (disposal of main undertaking).

("10% Placement Period").

Specific information required by Listing Rule 7.3A

Pursuant to and in accordance with Listing Rule 7.3A, information is provided in relation to the approval of the 10% Placement Facility as follows:

- a. If this Resolution is approved by Shareholders, the period for which the Shareholder approval of the 10% Placement Facility under Listing Rule 7.1A will be valid commences on the date of the Annual General Meeting at which the approval is obtained, being 5 November 2027, and expires on the first to occur of the following:
 - i. the date that is 12 months after the date of the Annual General Meeting at which the approval is obtained, being 5 November 2027;
 - ii. the time and date of the Company's next annual general meeting;
 - iii. the time and date of the approval by Shareholders of a transaction under Listing Rules 11.1.2 (a significant change to the nature or scale of activities) or 11.2 (disposal of main undertaking).
- b. The Equity Securities will be issued at an issue price of not less than 75% of the VWAP for the Company's Equity Securities in the same class calculated over the 15 trading days on which trades in that class were recorded immediately before:
 - i. the date on which the price at which the Equity Securities are to be issued is agreed by the Company and the recipient of the securities; or
 - ii. if the Equity Securities are not issued within 10 trading days of the date in paragraph (i) above, the date on which the Equity Securities are issued.
- c. The purposes for which the funds raised by an issue of Equity Securities under rule 7.1A.2 may be used by the Company include:
 - i. consideration for the acquisition(s) of new assets and investments, including the expenses associated with such acquisition(s); and
 - ii. continued expenditure on the Company's current business and/or general working capital.
- d. If this Resolution is approved by Shareholders and the Company issues Equity Securities under the 10% Placement Facility, the existing Shareholders' voting power in the Company will be diluted as shown in the below table. Shareholders may also be exposed to economic risk and voting dilution, including the following:
 - i. the market price for the Company's Equity Securities may be significantly lower on the date of the issue of the Equity Securities than on the date of the Annual General Meeting; and
 - ii. the Equity Securities may be issued at a price that is at a discount to the market price for the Company's Equity Securities on the issue date

which may have an effect on the amount of funds raised by the issue of the Equity Securities.

The below table shows the dilution of existing Shareholders on the basis of the market price of Shares as at \$0.017 (**Current Share Price**) and the current number of ordinary securities for variable "A" calculated in accordance with the formula in Listing Rule 7.1A.(2) as at the date of this Notice.

The table also shows:

- two examples where variable "A" has increased, by 50% and 100%. Variable "A" is based on the number of ordinary securities the Company has on issue. The number of ordinary securities on issue may increase as a result of issues of ordinary securities that do not require Shareholder approval (for example, a pro rata entitlements issue or scrip issued under a takeover offer) or future specific placements under Listing Rule 7.1 that are approved at a future Shareholders' meeting; and
- two examples of where the issue price of ordinary securities has decreased by 50% and increased by 100% as against the current market price.

Variable 'A' in Listing Rule 7.1A.2	Dilution Scenario	Assumed Issue Prices, based on:		
		50% decrease in Current Share Price \$0.0085	Current Share Price \$0.017	100% increase in Current Share Price \$0.034
Current Variable A 902,432,853 Shares	10% Voting Dilution	90,243,285 Shares		
	Funds raised	\$ 767,068	\$ 1,534,136	\$ 3,068,272
50% increase in current Variable A 1,353,649,280 Shares	10% Voting Dilution	135,364,928 Shares		
	Funds raised	\$ 1,150,602	\$ 2,301,204	\$ 4,602,408
100% increase in current Variable A 1,804,865,706 Shares	10% Voting Dilution	180,486,571 Shares		
	Funds raised	\$ 1,534,136	\$ 3,068,272	\$ 6,136,543

The table has been prepared on the following assumptions:

- The Company issues the maximum number of Equity Securities available under the 10% Placement Facility.
 - No Options are exercised into Shares before the date of the issue of the Equity Securities.
 - The 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%.
 - The table does not show an example of dilution that may be caused to a particular Shareholder by reason of placements under the 10% Placement Facility, based on that Shareholder's holding at the date of the Annual General Meeting.
 - The table shows only the effect of issues of Equity Securities under Listing Rule 7.1A, not under the 15% placement capacity under Listing Rule 7.1.
 - The issue of Equity Securities under the 10% Placement Facility consists only of Shares. If the issue of Equity Securities includes Quoted Options, it is assumed that those Quoted Options are exercised into Shares for the purpose of calculating the voting dilution effect on existing Shareholders.
 - The Current Share Price is \$0.017, being the closing price of the Shares on ASX on 16 September 2026.
- (e) The Company's allocation policy is dependent on the prevailing market conditions at the time of any proposed issue pursuant to the 10% Placement Facility. The identity of the allottees of Equity Securities will be determined on a case-by-case basis having regard to the factors including but not limited to the following:
- the methods of raising funds that are available to the Company, including but not limited to, rights issue or other issue in which existing security holders can participate;
 - the effect of the issue of the Equity Securities on the control of the Company;

- (iii) the financial situation and solvency of the Company; and
- (iv) advice from corporate, financial and broking advisers (if applicable).

The allottees under the 10% Placement Facility have not been determined as at the date of this Notice but may include existing substantial Shareholders, subject to compliance with Listing Rule 10.11, and/or new Shareholders who are not related parties or associates of a related party of the Company.

(f) Previous issues over the Last 12 Months – Listing Rule 7.3A.6

There have been 81,017,528 securities issued or agreed to be issued in the past 12 months preceding the date of the Annual General Meeting under Listing Rule 7.1A.2, representing 10% of the total number of equity securities on issue at the commencement of the relevant 12 month period.

ASX Listing Rule 7.3A.6 requires that the following information be provided to Shareholders

- i. the Shares were issued to institutional and sophisticated professional investors;
- ii. the number and class of securities issued were 81,017,528 fully paid ordinary shares;
- iii. the 81,017,528 fully paid ordinary shares were issued at a price of \$0.033 (3.3 cents) per Share;
- iv. the purpose of the issue was to raise funds for expanding commercialisation of the Company's own portfolio of proprietary diagnostic tests, including Active Syphilis and Liver function, deliver operational scale up to support increased demand for supply of Pascal cassettes for Lumos' FebriDx growth in the US and working capital alongside costs of the Capital Raising.

Board Recommendation

The Board believes that this Resolution is in the best interests of the Company and recommends that Shareholders vote in favour of this Resolution.

Voting Intention

The Chair of the Meeting intends to vote undirected proxies in favour of this Resolution.

Voting Exclusions

A voting exclusion statement for this resolution is set out in Note 5 above.

GLOSSARY

The following terms have the following meanings in this Explanatory Statement:

“\$” means Australian Dollars;

“**10% Placement Facility**” has the meaning as defined in the Explanatory Statement for Resolution 10;

“**10% Placement Period**” has the meaning as defined in the Explanatory Statement for Resolution 10;

“**Annual Report**” means the Directors’ Report, the Financial Report, and Auditor’s Report, in respect to the year ended 30 June 2026;

“**ASX**” means ASX Limited or the Australian Securities Exchange, as the context requires;

“**Auditor’s Report**” means the auditor’s report on the Financial Report;

“**AEDT**” means Australian Eastern Daylight Time.

“**Board**” means the Directors acting as the board of Directors of the Company or a committee appointed by such board of Directors;

“**Chair**” means the person appointed to chair the Meeting of the Company convened by the Notice;

“**Closely Related Party**” of a member of Key Management Personnel has the meaning given in section 9 of the Corporations Act:

“**Company**” means Atomo Diagnostics Limited ACN 142 925 684;

“**Constitution**” means the constitution of the Company as at the date of the Meeting;

“**Corporations Act**” means the Corporations Act 2001 (Cth);

“**Director**” means a Director of the Company;

“**Directors Report**” means the annual directors’ report prepared under Chapter 2M of the Corporations Act for the Company and its controlled entities;

“**Explanatory Statement**” means the explanatory statement which forms part of this Notice;

“**Financial Report**” means the annual financial report prepared under Chapter 2M of the Corporations Act for the Company and its controlled entities;

“**Key Management Personnel**” means persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any Director (whether executive or otherwise) of the Company;

“**Listing Rules**” means the Listing Rules of the ASX;

“**Meeting**” has the meaning given in the introductory paragraph of the Notice;

“**Notice**” means this Notice of Meeting including the Explanatory Statement;

“**Proxy Form**” means the proxy form attached to the Notice;

“**Remuneration Report**” means the remuneration report which forms part of the Directors’ Report of the Company for the financial year ended 30 June 2026 and which is set out in the 2026 Annual Report.

“**Resolution**” means a resolution referred to in the Notice;

“**Section**” means a section of the Explanatory Statement;

“**Security**” means an equity security or a debt security;

“**Share**” means a fully paid ordinary share in the capital of the Company;

“**Shareholder**” means shareholder of the Company;

“**Trading Day**” means a day determined by ASX to be a trading day in accordance with the Listing Rules; and

“**VWAP**” means volume weighted average market price as defined in Listing Rule 19.12.

Annexure A:

Key Terms of the Free Attaching Options and Broker Options:

(a) **Entitlement**

Each Option entitles the holder to subscribe for one fully paid ordinary Share.

(b) **Exercise Price and Expiry Date**

The Options are exercisable at \$0.045 each and expire at 5.00pm on the date which is 2.5 years from their date of issue (**Expiry Date**). Any Option not exercised by the Expiry Date will automatically expire.

(c) **Exercise**

To exercise the Options, the Option holder must give the Company:

- (i) a written exercise notice (in the form approved by the Board from time to time) specifying the number of Options being exercised and Shares to be issued; and
- (ii) payment of the exercise price for the Shares, the subject of the exercise notice, by way of bank cheque or by other means of payment approved by the Company.

The Options will be deemed to have been exercised on the date the exercise notice is lodged with the Company and cleared funds for the exercise price has been received.

(d) **Timing of issue of Shares upon exercise**

Within 5 Business Days (as defined in the Listing Rules) after the exercise of the Options in accordance with paragraph (c) above, the Company must issue the Option holder the resultant Shares.

(e) **Ranking of Shares**

Subject to the Constitution, all Shares issued on the exercise of Options will rank in all respects (including rights relating to dividends) equally with the existing ordinary shares of the Company at the date of issue.

(f) **Quotation of Options**

The Company will not apply to ASX for quotation of the Options.

(g) **Quotation of Shares on exercise**

The Company will apply to ASX for Official Quotation of the Shares issued on exercise of Options.

(h) **Participation rights**

The Option holder is not entitled to participate in any issue to existing Shareholders of Securities unless they have exercised their Options before the "record date" for determining entitlements to the issue of Securities and participate as a result of holding Shares.

(i) **Dividend rights**

The Options do not confer any entitlement to a dividend, whether fixed or at the discretion of the Directors, during the currency of the Options without exercising the Options.

(j) **Voting rights**

The Options do not confer any right to vote at meetings of members of the Company, except as required by law, during the currency of the Options without first exercising the Options.

(k) **Capital return**

The Options do not confer any right to a return of capital, whether in a winding up, upon a reduction of capital or otherwise, and similarly do not confer any right to participate in the surplus profit or assets of the Company upon a winding up, in each case, during the currency of the Options without exercising the Options.

(l) **Reorganisation**

If there is a reorganisation (including consolidation, subdivision, reduction or return) of the share capital of the Company, then the rights of the Option holder (including the number of Options to which the Option holder is entitled to and the exercise price) is changed to the extent necessary to comply with the Listing Rules applying to a reorganisation of capital at the time of the reorganisation.

(m) **Amendments**

The number and exercise price of the Options remains the same regardless of whether the Company makes a bonus issue of Shares or other Securities to Shareholders.

(n) **Adjustments**

Any calculations or adjustments which are required to be made will be made by the Board and will, in the absence of manifest error, be final and conclusive and binding on the Company and the Option holder.

(o) **Governing law**

The terms and the rights and obligations of the Option holder are governed by the laws of New South Wales. The Option holder irrevocably and unconditionally submits to the non-exclusive jurisdiction of the courts of New South Wales.

Annexure B:

Summary of the Material Terms of Atomo's Employee Option Plan

Term	Description
Eligible participants	Eligible participants include natural persons who are a: (a) casual, permanent full-time or permanent part-time employee of an Employing Company; (b) a person who provides services to an Employing Company; (c) director of an Employing Company; or (d) a prospective person to whom subparagraph (a), (b) or (c) may apply. of the Company or an Associated Company whom the Board determines to be eligible to participate in the Option Plan, or any other person who is declared by the Board in its sole and absolute discretion to be eligible to participate in the Plan, provided that such person is an ESS Participant. (Eligible Option Participant).
Plan Interests	Eligible Option Participants will be provided with an opportunity to acquire a financial interest in the Company, which will align their interests more closely with shareholders and provide greater incentive for them to focus on the Company's longer-term goals.
Quantum	The number of Awards offered to an Eligible Option Participant will be specified in the invitation made to that Eligible Option Participant.
Terms and conditions	The Board may from time to time invite an Eligible Option Participant to participate in the Option Plan. Invitations will be subject to such terms as the Board determines and will specify, amongst other things, the following: (a) any Awards fee that may be applicable; (b) the exercise price of the Awards; (c) the duration of the Awards, including the first and last exercise date of the Awards; and (d) the time period for making an application to participate in the Option Plan; Following receipt by an Eligible Option Participant of an invitation as described above, the Eligible Option Participant may make an application by delivering to the Company a duly completed and executed application form within the closing time specified in the invitation or in accordance with any other procedure set out in the invitation. The Board may then decide to accept or reject the offer made by the Eligible Option Participant
Restrictions	An Option Participant must not assign, transfer, sell or grant a security interest or otherwise deal with an Award. An Option Participant may only exercise an Award in accordance with the terms of the Option Plan. If the Company offers shareholders other securities, the Board will determine whether the other securities are to be offered to Option Participants on the exercise of Awards or whether any other equivalent securities, interest or rights will be offered to them if the other securities are not available, and the basis thereof, to the intent that on the exercise of Awards the Option Participants will be treated whenever possible as if they were shareholders at the date that the Awards are granted to the Option Participant.
Amendments	The Board may at any time amend the Option Plan or waive or amend the application of any of the rules under the Option Plan in relation to an Eligible Option Participant at any time and a change may be given retrospective effect. However, where any amendments will reduce any of the Option Participants' rights in respect of their Awards, the Board must obtain the prior written consent of at least 75% of the Option Participants affected by

	the change unless the amendment is to correct a manifest error or for the purpose of complying with applicable laws or to take into consideration possible adverse tax implications to the Option Plan arising from changes to relevant tax guidance.
--	---



All correspondence to:

-  **By Mail** Boardroom Pty Limited
GPO Box 3993
Sydney NSW 2001 Australia
-  **By Fax** +61 2 9290 9655
-  **Online** www.boardroomlimited.com.au
-  **By Phone** (within Australia) 1300 737 760
(outside Australia) +61 2 9290 9600

YOUR VOTE IS IMPORTANT

For your vote to be effective it must be recorded **before 10:00am (AEDT) on Tuesday, 3 November 2026.**

TO VOTE ONLINE

STEP 1: VISIT <https://www.votingonline.com.au/at1agm2026>

STEP 2: Enter your Postcode (if within Australia) OR Country of Residence (if outside Australia)

STEP 3: Enter your Voting Access Code (VAC):

PLEASE NOTE: For security reasons it is important you keep the above information confidential.



BY SMARTPHONE



Scan QR Code using smartphone QR Reader App

TO VOTE BY COMPLETING THE VOTING FORM

The voting form can be used to either vote directly (Section 1) OR appoint a proxy to vote on your behalf (Section 2).

SECTION 1: DIRECT VOTING

If you wish to vote directly, you should clearly mark the box in Section 1 and the boxes in Section 3 to indicate your voting instruction for each resolution. Please only mark either "for" or "against" for each resolution. **Do not mark the "abstain" box if you are voting directly.** If no direction is given on a resolution, or if you complete both the boxes in Section 1 and 2, your vote may be passed to the Chair of the Meeting as your proxy. Securityholders, custodians and nominees may identify on the Voting Form the total number of votes in each of the categories "for" and "against" and their votes will be valid. The Chair's decision as to whether a direct vote is valid is final and conclusive.

SECTION 2: APPOINTMENT OF PROXY

Indicate who you want to appoint as your Proxy.

If you wish to appoint the Chair of the Meeting as your proxy, mark the box in Section 2. If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the full name of that individual or body corporate. If you leave this section blank, or your named proxy does not attend the meeting or does not vote on a poll in accordance with your instructions, the Chair of the Meeting will be your proxy by default. A proxy need not be a Securityholder of the company. Do not write the name of the issuer company or the registered Securityholder in the space.

Appointment of a Second Proxy

You are entitled to appoint up to two proxies to attend the meeting and vote on a poll. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by contacting the company's securities registry or you may copy this form.

To appoint a second proxy, you must

(a) complete two forms. On each form state the percentage of your voting rights or the number of securities applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded.

(b) return both forms together in the same envelope.

SECTION 3: VOTING DIRECTIONS

To cast your direct vote or to direct your proxy how to vote, place a mark in one of the boxes opposite each resolution. All your securities will be voted in accordance with such a direction unless you indicate only a portion of securities are to be voted on any resolution by inserting the percentage or number that you wish to vote in the appropriate box or boxes. The sum of the votes cast must not exceed your voting entitlement or 100%. If you do not mark any of the boxes on a given resolution, your proxy may vote as he or she chooses (subject to any voting restrictions that apply to your proxy). If you mark more than one box on a resolution for all your securities your vote on that resolution will be invalid.

Proxy which is a Body Corporate

Where a body corporate is appointed as your proxy, the representative of that body corporate attending the Meeting must have provided an "Appointment of Corporate Representative" prior to admission. An Appointment of Corporate Representative form can be obtained from the company's securities registry.

SECTION 4: SIGN THE FORM

The form **must** be signed as follows:

Individual: This form is to be signed by the Securityholder.

Joint Holding: where the holding is in more than one name, all the Securityholders should sign.

Power of Attorney: to sign under a Power of Attorney, you must have already lodged it with the registry. Alternatively, attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: this form must be signed by a Director jointly with either another Director or a Company Secretary. Where the company has a Sole Director who is also the Sole Company Secretary, this form should be signed by that person. **Please indicate the office held by signing in the appropriate place.**

LODGE MENT

Voting Forms (and any Power of Attorney under which it is signed) must be received no later than 48 hours before the commencement of the Meeting, therefore **before 10:00am (AEDT) on Tuesday, 3 November 2026.** Any Voting Form received after that time will not be valid for the scheduled Meeting.

Voting forms may be lodged using the enclosed Reply-Paid Envelope or:

 **Online**

<https://www.votingonline.com.au/at1agm2026>

 **By Smartphone**

Scan the QR Code

 **By Fax**

+61 2 9290 9655

 **By Mail**

Boardroom Pty Limited

GPO Box 3993,
Sydney NSW 2001 Australia

 **In Person**

Boardroom Pty Limited Level 8,
210 George Street, Sydney
NSW 2000 Australia

☐

Your Address
This is your address as it appears on the company's share register. If this is incorrect, please mark the box with an "X" and make the correction in the space to the left. Securityholders sponsored by a broker should advise their broker of any changes. **Please note, you cannot change ownership of your securities using this form.**

VOTING FORM

SECTION 1: DIRECT VOTING

☐

I/We being a Securityholder/s of **Atomo Diagnostics Limited** (Company) and entitled to attend and vote hereby elect to vote directly at the **Annual General Meeting** of the Company to be held **virtually at <https://vistra.zoom.us/webinar/register/WN.CLGwUIGLSiWUuPGaVPiFZQ> on Thursday, 5 November 2026 at 10:00am (AEDT)** and at any adjournment of that Meeting.

SECTION 2: APPOINTMENT OF PROXY

I/We being a Securityholder/s of **Atomo Diagnostics Limited** (Company) and entitled to attend and vote hereby appoint: the

☐

Chair of the Meeting (mark box)

OR if you are **NOT** appointing the Chair of the Meeting as your proxy, please write the name of the person or body corporate (excluding the registered Securityholder) you are appointing as your proxy below

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chair of the Meeting as my/our proxy at the **Annual General Meeting** of the Company to be held **virtually at <https://vistra.zoom.us/webinar/register/WN.CLGwUIGLSiWUuPGaVPiFZQ> on Thursday, 5 November 2026 at 10:00am (AEDT)** and at any adjournment or of that Meeting, to act on my/our behalf and to vote in accordance with the following directions or if no directions have been given, as the proxy sees fit.

The Chair of the Meeting is authorised to exercise undirected proxies on remuneration-related matters. If I/we have appointed the Chair of the Meeting as my/our proxy or the Chair of the Meeting becomes my/our proxy by default and I/we have not directed my/our proxy how to vote in respect of **Resolutions 1, 6, 7, 8 and 9**, I/we expressly authorise the Chair of the Meeting to exercise my/our proxy in respect of these resolutions even though **Resolutions 1, 6, 7, 8 and 9** are connected with the remuneration of a member of the key management personnel for the Company.

The Chair of the Meeting intends to vote undirected proxies **in favour** of all items of business.

SECTION 3: VOTING DIRECTIONS

		For	Against	Abstain*
Resolution 1	Adoption of Remuneration Report	☐	☐	☐
Resolution 2	Re-Election of Mr Patrick Cook as a Director of the Company	☐	☐	☐
Resolution 3	Ratification of prior issue of 90,909,091 Ordinary Shares and 45,454,536 Options as part of the Placement	☐	☐	☐
Resolution 4	Ratification of prior issue of Broker Options to Joint Lead Managers	☐	☐	☐
Resolution 5	Ratification of prior issue of 1,348,480 Ordinary Shares and 674,229 Options as part of the Share Purchase Plan (SPP)	☐	☐	☐
Resolution 6	Approval of Employee Option Plan	☐	☐	☐
Resolution 7	Approval to grant Options to Mr Patrick Cook (and/or his nominee(s))	☐	☐	☐
Resolution 8	Approval to grant Options to Mr Anthony May (and/or his nominee(s))	☐	☐	☐
Resolution 9	Approval to grant Options to Dr Cheri Walker (and/or her nominee(s))	☐	☐	☐
Resolution 10	Approval of 10% Placement Facility (Special Resolution)	☐	☐	☐

STEP 3 SIGNATURE OF SECURITYHOLDERS
This form must be signed to enable your directions to be implemented.

Individual or Securityholder 1

Securityholder 2

Securityholder 3

Sole Director and Sole Company Secretary

Director

Director / Company Secretary